3/20/2013

XDx said California's Medicaid program has started reimbursing for the use of AlloMap, a molecular diagnostic test for heart transplant rejection. The company said more than 200 U.S. insurers now cover the test, with more than 80% of tests in 2012 reimbursed.

Related Summaries